Guidance
Update information
March 2021: We produced a statement clarifying our recommendations on unlicensed cannabis-based medicinal products for severe treatment-resistant epilepsy, which should be read alongside the recommendations.
March 2021: We produced a statement clarifying our recommendations on unlicensed cannabis-based medicinal products for severe treatment-resistant epilepsy, which should be read alongside the recommendations.